Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Rating of “Moderate Buy” by Analysts

Candel Therapeutics, Inc. (NASDAQ:CADL) has been assigned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have given a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $18.00.

A number of research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Candel Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, June 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Candel Therapeutics in a report on Monday, April 20th. Canaccord Genuity Group restated a “buy” rating and set a $25.00 price objective on shares of Candel Therapeutics in a report on Friday, March 13th. Zacks Research raised Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Finally, Citigroup decreased their target price on Candel Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a research note on Friday, March 13th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of CADL. BNP Paribas Financial Markets boosted its holdings in Candel Therapeutics by 128.2% during the third quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock worth $40,000 after purchasing an additional 4,439 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in Candel Therapeutics by 361.7% during the second quarter. Tower Research Capital LLC TRC now owns 9,608 shares of the company’s stock worth $49,000 after purchasing an additional 7,527 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in Candel Therapeutics during the fourth quarter worth $51,000. ProShare Advisors LLC acquired a new position in Candel Therapeutics during the fourth quarter worth $59,000. Finally, Invesco Ltd. acquired a new position in Candel Therapeutics during the first quarter worth $59,000. 13.93% of the stock is owned by institutional investors and hedge funds.

Candel Therapeutics Trading Up 2.2%

CADL opened at $9.47 on Friday. The company has a current ratio of 28.05, a quick ratio of 28.05 and a debt-to-equity ratio of 0.34. The stock has a market capitalization of $693.87 million, a PE ratio of -9.66 and a beta of -0.49. Candel Therapeutics has a 1-year low of $4.35 and a 1-year high of $9.61. The firm has a 50-day moving average price of $7.91 and a two-hundred day moving average price of $6.34.

Candel Therapeutics (NASDAQ:CADL) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.16. As a group, equities analysts anticipate that Candel Therapeutics will post -0.97 earnings per share for the current fiscal year.

Candel Therapeutics Company Profile

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.